India seeks import of COVID-19 vaccines; move to bolster domestic producers

14 April 2021

The Indian government has decided to fast-track vaccine approvals that have already been authorized by one of four foreign drug regulators or the World Health Organization, clearing the way for the emergency approval for COVID-19 vaccines amid a huge surge in infections and deaths.

While the move will potentially boost the country’s pandemic response through possible imports of Pfizer (NYSE: PFE), Moderna (Nasdaq: MRNA) and Johnson & Johnson (NYSE: JNJ) shots, it has also opened the floodgates for domestic manufacturers, reports The Pharma Letter’s India correspondent.

India reported a record single-day rise of 184,372 new coronavirus infections pushing the total tally of cases to 13.87 million, while the active cases surpassed the 1.3 million mark, according to the Union Health Ministry data updated on Wednesday.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK